Boehringer Ingelheim Venture

Boehringer Ingelheim Venture Fund (BIVF) is a dynamic venture capital arm of Boehringer Ingelheim, investing in groundbreaking biotechnologies and therapeutics. BIVF's notable portfolio includes companies like HepaRegenix, focusing on liver regeneration; Imcheck Therapeutics, developing novel cancer immunotherapies; and Asgard Therapeutics, pioneering gene therapy-mediated cancer treatments. BIVF primarily targets biotech startups in areas such as oncology, regenerative medicine, infectious diseases, and digital health, with a strong emphasis on early-stage investments. They invest globally, with significant activity in Europe, the US, and Asia, aiming to foster innovation that aligns with Boehringer Ingelheim's strategic interests. Their strategy involves taking minority stakes and actively supporting companies through the pre-seed, seed, and series A stages. BIVF typically leads funding rounds, providing crucial support in both capital and expertise. They prefer startups that are exploring novel therapeutic approaches with the potential for significant clinical impact. For startups looking to engage with BIVF, it’s essential to have a groundbreaking technology with strong preclinical or early clinical data. They value strategic alignment with Boehringer Ingelheim’s therapeutic areas and appreciate a collaborative approach from entrepreneurs.